AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

Betsy Goodfellow | May 17, 2024 | News story | Research and Development |  AstraZeneca, COVID-19, Immunology, clinical trial 

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly AZD3152).

The investigational long-acting antibody (LAAB) demonstrated a statistically significant reduction in the incidence of symptomatic COVID-19 compared to a control group being treated with tixagevimab/cilgavimab or placebo, in an immunocompromised patient population.

The trial met both dual primary endpoints, the first being the relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant, and the second being the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.

Iskra Reic, executive vice president of vaccines and immune therapies at AstraZeneca, commented: “Immunocompromised patients currently have limited or no options for COVID-19 protection and continue to face a significant burden of disease, despite often being fully vaccinated. Sipavibart has the potential to prevent COVID-19 in the immunocompromised and we will now work with regulatory authorities globally to bring sipavibart to these vulnerable patients.”

The data is expected to be presented at an upcoming medical meeting, and the company is already in conversation with the relevant regulatory authorities around potential authorisation or approval pathways.

Betsy Goodfellow